It was further shown that a CCR4 antagonist CCR4-351 inhibited Treg cell recruitment into tumor tissues in mice bearing murine pancreatic and colon cancers, and augmented tumor-specific immune responses [63]. This evidence concerns the gene CCR4 and neoplasm.